Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2026)

Ionis Pharmaceuticals' Other Accumulated Expenses history runs 11 years deep, the most recent figure standing at $25.1 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 10.27% year-over-year to $25.1 million; the TTM figure through Jun 2026 stood at $25.1 million (up 10.27% YoY), while the FY2025 annual figure was $28.3 million, up 45.34% from the prior year.
• Other Accumulated Expenses for Q2 2026 stood at $25.1 million, down from $26.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $29.6 million in Q4 2023, with the low at $9.6 million in Q1 2023.
• The 5-year median for Other Accumulated Expenses is $20.8 million (2024), against an average of $19.7 million.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses surged 142.65% in 2023, then slumped 34.25% in 2024.
• Ionis Pharmaceuticals' Other Accumulated Expenses stood at $12.2 million in 2022, then soared by 142.65% to $29.6 million in 2023, then plunged by 34.25% to $19.5 million in 2024, then surged by 45.34% to $28.3 million in 2025, then fell by 11.09% to $25.1 million in 2026.
• Business Quant data shows IONS's Other Accumulated Expenses at $25.1 million in Q2 2026, $26.1 million in Q1 2026, and $28.3 million in Q4 2025.